Purple Biotech Ltd ADR (PPBT) Stock Price, Quote & News

Company Profile

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 933 3121

Fax: 972 3 509 7196

Website: purple-biotech.com

Address:

4 Oppenheimer Street, Science Park, Rehovot, Israel

Dr_HIM Jul. 7 at 7:00 PM

$PPBT Tase is like a shark treading water 50 meters off the coastline 🌊🦈 Smelled blood but can’t find its prey 🖕🏽

0 · Reply

Duediligence20 Jul. 7 at 6:59 PM

$PPBT When is the last time you saw Company Directors buying shares here? Oh yea that’s right they probably have a Non Disclosure Agreement prohibiting that🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣. Plus this is probably Top Secret Shit involved with the Cancer Moon Shot.🤦‍♂️🤦‍♂️🤦‍♂️

0 · Reply

Oxinternet Jul. 7 at 3:57 PM

$PPBT If you just threw $1M at this and came back 10 years later, you’d probably have $999,999. 🙄

1 · Reply

Smittysixty Jul. 7 at 3:53 PM

$PPBT Catalysts on Deck 🚨 📆 Q2 Financials + 13Fs due by Aug 15 🧪 CM24 Ph2b initiation expected any day now 📑 ESMO abstract titles: • Regular – July 25 • Late-breaking – Sept 20 🎤 ESMO Congress: Oct 17–21 NT219: Unfinished Story 🧩 ~75% of clinical data still unreleased from the Ph1/2 trial that wrapped 425 days ago 🔍 What’s still under wraps: • 8 SCCHN patients • 27 monotherapy patients • Colorectal combo cohort (n=?) Silent data. Ticking clock. Catalysts stacking. FUD Patrol distracting.

0 · Reply

BiotechBonesaw Jul. 7 at 3:03 PM

$PPBT it’s not quiet for $IMRX 🚀

0 · Reply

Mattblock Jul. 7 at 2:58 PM

$PPBT enjoying the quietness

0 · Reply

PurpleDreamer Jul. 7 at 2:34 PM

$PPBT High volume early in the morning...one of these days....

0 · Reply

Duediligence20 Jul. 7 at 1:49 PM

$PPBT Keep The Hope Light On People. “These results not only validate CM24’s potential but also position Purple Biotech to expand its pipeline into broader cancer applications. With a planned Phase 2b trial targeting high-CEACAM1 patients, the company is tapping into precision oncology—a sector that continues to draw investor enthusiasm due to its game-changing innovation.” We know when will the rest of the world discover us or are we being played?🤔

1 · Reply

Stocksavior14 Jul. 7 at 1:25 PM

$PPBT the permabulls will be right about the deals when pigs officially have wings coming out of their bodies LOL

0 · Reply

Smittysixty Jul. 7 at 1:10 PM

$PPBT 🚨 Big NT219 Data Gaps 🚨 Phase 1/2 trial ended May 8, 2024 — 425 days ago Last data shared: Feb 26, 2024 at ESMO TAT Only ~25% of efficacy data has been disclosed 📉 8 SCCHN patient data remains 📉 27 patients in NT219 monotherapy arm 📉 Colorectal combo arm (patient count undisclosed) 📉 No DoR, PFS, OS 👀 Yet Phase 2 already initiated 💡 All eyes now on ESMO Congress 2025 for the full reveal

0 · Reply

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

May 21, 2025, 7:10 AM EDT - 6 weeks ago

Purple Biotech Reports First Quarter 2025 Financial Results

May 12, 2025, 7:30 AM EDT - 2 months ago

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

Apr 28, 2025, 8:28 AM EDT - 2 months ago

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

Mar 10, 2025, 8:57 AM EDT - 4 months ago

Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

Feb 18, 2025, 7:00 AM EST - 4 months ago

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

Dec 5, 2024, 7:13 AM EST - 7 months ago

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 3, 2024, 8:23 AM EST - 7 months ago

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 2, 2024, 9:18 AM EST - 7 months ago

Why Is Purple Biotech Stock Trading Higher On Monday?

Nov 15, 2024, 7:00 AM EST - 8 months ago

Purple Biotech Reports Third Quarter 2024 Financial Results

Nov 4, 2024, 7:50 AM EST - 8 months ago

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Oct 25, 2024, 7:20 AM EDT - 9 months ago

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 10, 2024, 7:30 AM EDT - 9 months ago

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Sep 18, 2024, 6:30 AM EDT - 10 months ago

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

Aug 30, 2024, 7:00 AM EDT - 11 months ago

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Aug 16, 2024, 8:12 AM EDT - 11 months ago

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights

Jul 25, 2024, 7:35 AM EDT - 1 year ago

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule

Jul 10, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024

Jul 2, 2024, 4:00 PM EDT - 1 year ago

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

Jul 1, 2024, 9:00 AM EDT - 1 year ago

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

Jun 27, 2024, 7:45 AM EDT - 1 year ago

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

Jun 1, 2024, 8:00 AM EDT - 1 year ago

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer

May 21, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech Reports First Quarter 2024 Financial Results

Apr 25, 2024, 7:00 AM EDT - 1 year ago

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Mar 14, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

Mar 5, 2024, 7:55 AM EST - 1 year ago

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Feb 27, 2024, 7:00 AM EST - 1 year ago

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Feb 13, 2024, 7:00 AM EST - 1 year ago

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

Feb 1, 2024, 7:30 AM EST - 1 year ago

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Dec 20, 2023, 8:05 AM EST - 1 year ago

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

Dec 14, 2023, 6:50 AM EST - 1 year ago

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

Nov 21, 2023, 6:50 AM EST - 1 year ago

Purple Biotech Reports Third Quarter 2023 Financial Results

Oct 19, 2023, 3:55 PM EDT - 1 year ago

Purple Biotech Announces Closing of $5 Million Registered Direct Offering

Oct 17, 2023, 8:00 AM EDT - 1 year ago

Purple Biotech Announces $5 Million Registered Direct Offering

Oct 6, 2023, 7:50 AM EDT - 1 year ago

Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action

Oct 3, 2023, 7:50 AM EDT - 1 year ago

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

Aug 22, 2023, 9:29 AM EDT - 2 years ago

Purple Biotech Reports Second Quarter 2023 Financial Results

Jul 11, 2023, 8:15 AM EDT - 2 years ago

Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

May 16, 2023, 4:00 PM EDT - 2 years ago

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

Apr 19, 2023, 8:15 AM EDT - 2 years ago

Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors

Apr 18, 2023, 7:00 AM EDT - 2 years ago

Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference

Mar 24, 2023, 7:00 AM EDT - 2 years ago

Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron

Feb 14, 2023, 7:01 AM EST - 2 years ago

Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial

Feb 8, 2023, 7:12 AM EST - 2 years ago

Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results

Nov 15, 2022, 7:00 AM EST - 2 years ago

Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis

Nov 8, 2022, 7:53 AM EST - 2 years ago

Purple Biotech Reports Third Quarter 2022 Financial Results

Nov 2, 2022, 7:37 AM EDT - 2 years ago

Purple Biotech Appoints Lior Fhima as Chief Financial Officer

Aug 4, 2022, 7:30 AM EDT - 3 years ago

Purple Biotech Reports Second Quarter 2022 Financial Results

Jul 14, 2022, 7:30 AM EDT - 3 years ago

Purple Biotech Announces Executive Leadership Changes

May 27, 2022, 7:15 AM EDT - 3 years ago

Purple Biotech Presents Phase 1 Interim Monotherapy Data for NT219 at ASCO 2022, Demonstrating Encouraging Safety & Efficacy Profile

Dr_HIM Jul. 7 at 7:00 PM

$PPBT Tase is like a shark treading water 50 meters off the coastline 🌊🦈 Smelled blood but can’t find its prey 🖕🏽

0 · Reply

Duediligence20 Jul. 7 at 6:59 PM

0 · Reply

Oxinternet Jul. 7 at 3:57 PM

$PPBT If you just threw $1M at this and came back 10 years later, you’d probably have $999,999. 🙄

1 · Reply

Smittysixty Jul. 7 at 3:53 PM

0 · Reply

BiotechBonesaw Jul. 7 at 3:03 PM

$PPBT it’s not quiet for $IMRX 🚀

0 · Reply

Mattblock Jul. 7 at 2:58 PM

$PPBT enjoying the quietness

0 · Reply

PurpleDreamer Jul. 7 at 2:34 PM

$PPBT High volume early in the morning...one of these days....

0 · Reply

Duediligence20 Jul. 7 at 1:49 PM

1 · Reply

Stocksavior14 Jul. 7 at 1:25 PM

$PPBT the permabulls will be right about the deals when pigs officially have wings coming out of their bodies LOL

0 · Reply

Smittysixty Jul. 7 at 1:10 PM

0 · Reply

SirGay_LoveRaw Jul. 7 at 8:16 AM

$PPBT What if this board was right predicting every single buyout deal, but then the Big Pharma lawyers were like: - You promised secrecy, and then you leak the deal on a ST board!!! - We didn't leak anything, I promise, the pocket tweet was a honest mistake, the Toblerone was just chocolate... - We don't believe you, the deal is canceled!

0 · Reply

Stocksavior14 Jul. 6 at 3:49 AM

$PPBT so you’re going to donate 99% of what you might make here? LOL

0 · Reply

St0ckPwn Jul. 6 at 12:33 AM

$PPBT 7 months and counting without a single green candle in sight

1 · Reply

Randy_Lahey_Trevor_Corey Jul. 5 at 6:02 PM

$PPBT if I make any money in my lifetime off this stock I’ll donate $17 to the nearest synagogue

0 · Reply

Purplepayday Jul. 4 at 3:52 PM

$PPBT Halted on Tase… And halted here on Nasdaq 🤔 That can only mean one thing 🧐 …

2 · Reply

PPBT4LYFE Jul. 3 at 8:49 PM

$PPBT another week closer. Markets closed tomorrow.

1 · Reply

BiotechBonesaw Jul. 3 at 2:55 PM

$NVCR is undervalued. But if you want to invest in much hotter pancreatic cancer biotechs then $IMRX & $PPBT are much more exciting short & long 🚀 GLB 👍 ☘️ 🐂

0 · Reply

Smittysixty Jul. 3 at 2:50 PM

$PPBT Let’s assume that NT-219 full phase 1/2 data will drop at ESMO (LBA titles Sept 20). Hard to picture a billion-dollar NT-219 deal when Purple trades at $7M… unless a CM-24 transaction rewrites the narrative first. Value isn’t just in the data. It’s in the timing. ⏳ Clock’s ticking on CM-24.

0 · Reply

Smittysixty Jul. 3 at 2:47 PM

$PPBT 421 days since NT-219 Phase 1/2 completed. Still no full results. 100mg cohort? Silent. ESMO abstracts drop Sept 20. The most likely venue for it IMO.

1 · Reply

Smittysixty Jul. 3 at 12:11 AM

$PPBT If anonymous FUD accounts spent a fraction of their time researching the science instead of attacking those who do, they might actually build confidence in the stock. But that’s not their game. They don’t focus on the company—they fixate on silencing anyone sharing facts. That says more about their motives than it does about mine.

2 · Reply

LarryHParker Jul. 2 at 9:52 PM

$PPBT

2 · Reply

LarryHParker Jul. 2 at 9:51 PM

$PPBT 🤣

4 · Reply

Market Cap	3.30M
Revenue (ttm)	0.00
Net Income (ttm)	-7.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	24,300
Avg Vol	130,346
Day's Range	N/A - N/A
Shares Out	1.33M
Stochastic %K	92%
Beta	0.41
Analysts	Strong Sell
Price Target	$34.00